Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin 10 mg and insulin resistance in type 2 diabetes mellitus
2014-005377-36Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin 10 mg once daily with Placebo (2 arms). Primary endpoints: Body weight and other anthropometric measures, Insulin sensitivity in skeletal muscle and 1 more. Started Jan 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-005377-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005377-36.